NASDAQ: AVXL
Anavex Life Sciences Corp Stock Forecast, Predictions & Price Target

Analyst price target for AVXL

Based on 2 analysts offering 12 month price targets for Anavex Life Sciences Corp

Min Forecast
$42.00+342.11%
Avg Forecast
$44.00+363.16%
Max Forecast
$46.00+384.21%

Should I buy or sell AVXL stock?

Based on 2 analysts offering ratings for Anavex Life Sciences Corp.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AVXL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AVXL as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their AVXL stock forecasts and price targets.

AVXL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-07
lockedlocked$00.00+00.00%2025-04-07

1 of 1

Forecast return on equity

Is AVXL forecast to generate an efficient return?

Company
N/A
Industry
142.9%
Market
80.27%

Forecast return on assets

Is AVXL forecast to generate an efficient return on assets?

Company
N/A
Industry
35.65%

AVXL earnings per share forecast

What is AVXL's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.69
Avg 2 year Forecast
-$0.66

AVXL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVXL$9.50$44.00+363.16%Strong Buy
RCKT$7.63$43.00+463.56%Strong Buy
QURE$14.76$38.22+158.96%Buy
CVAC$3.55$14.00+294.37%Strong Buy
DAWN$7.78$31.00+298.46%Strong Buy

Anavex Life Sciences Stock Forecast FAQ

Is Anavex Life Sciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AVXL) stock is to Strong Buy AVXL stock.

Out of 2 analysts, 1 (50%) are recommending AVXL as a Strong Buy, 1 (50%) are recommending AVXL as a Buy, 0 (0%) are recommending AVXL as a Hold, 0 (0%) are recommending AVXL as a Sell, and 0 (0%) are recommending AVXL as a Strong Sell.

If you're new to stock investing, here's how to buy Anavex Life Sciences stock.

What is AVXL's earnings growth forecast for 2025-2026?

(NASDAQ: AVXL) Anavex Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Anavex Life Sciences's earnings in 2025 is -$46,491,000.On average, 1 Wall Street analyst forecast AVXL's earnings for 2025 to be -$58,694,297, with the lowest AVXL earnings forecast at -$58,694,297, and the highest AVXL earnings forecast at -$58,694,297.

In 2026, AVXL is forecast to generate -$56,142,371 in earnings, with the lowest earnings forecast at -$56,142,371 and the highest earnings forecast at -$56,142,371.

What is AVXL's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: AVXL) forecast ROE is N/A, which is considered weak.

What is AVXL's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AVXL price target, the average AVXL price target is $44.00, with the highest AVXL stock price forecast at $46.00 and the lowest AVXL stock price forecast at $42.00.

On average, Wall Street analysts predict that Anavex Life Sciences's share price could reach $44.00 by Apr 7, 2026. The average Anavex Life Sciences stock price prediction forecasts a potential upside of 363.16% from the current AVXL share price of $9.50.

What is AVXL's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: AVXL) Anavex Life Sciences's current Earnings Per Share (EPS) is -$0.55. On average, analysts forecast that AVXL's EPS will be -$0.69 for 2025, with the lowest EPS forecast at -$0.69, and the highest EPS forecast at -$0.69. In 2026, AVXL's EPS is forecast to hit -$0.66 (min: -$0.66, max: -$0.66).

What is AVXL's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: AVXL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.65%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.